Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. raised its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1,251.2% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 206,095 shares of the pharmaceutical company’s stock after purchasing an additional 190,842 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 0.08% of Vertex Pharmaceuticals worth $91,753,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in VRTX. Delta Financial Advisors LLC increased its stake in shares of Vertex Pharmaceuticals by 15.5% in the second quarter. Delta Financial Advisors LLC now owns 788 shares of the pharmaceutical company’s stock worth $351,000 after buying an additional 106 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Vertex Pharmaceuticals by 7.3% during the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 524,925 shares of the pharmaceutical company’s stock worth $233,697,000 after acquiring an additional 35,858 shares in the last quarter. Freemont Management S.A. increased its position in shares of Vertex Pharmaceuticals by 244.8% in the 2nd quarter. Freemont Management S.A. now owns 20,000 shares of the pharmaceutical company’s stock worth $8,904,000 after purchasing an additional 14,200 shares during the last quarter. Aviva PLC raised its stake in shares of Vertex Pharmaceuticals by 6.6% in the 2nd quarter. Aviva PLC now owns 192,660 shares of the pharmaceutical company’s stock valued at $85,772,000 after purchasing an additional 11,970 shares in the last quarter. Finally, Los Angeles Capital Management LLC lifted its position in shares of Vertex Pharmaceuticals by 28.3% during the second quarter. Los Angeles Capital Management LLC now owns 33,014 shares of the pharmaceutical company’s stock worth $14,698,000 after purchasing an additional 7,291 shares during the last quarter. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Price Performance

Shares of VRTX opened at $409.47 on Friday. The company has a market cap of $104.98 billion, a P/E ratio of 29.27 and a beta of 0.36. The stock has a fifty day moving average price of $404.55 and a 200 day moving average price of $429.56. Vertex Pharmaceuticals Incorporated has a 12 month low of $362.50 and a 12 month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.58 by $0.22. The company had revenue of $3.08 billion for the quarter, compared to analysts’ expectations of $3.05 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The firm’s quarterly revenue was up 11.0% compared to the same quarter last year. During the same period last year, the business posted $4.38 earnings per share. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Analyst Upgrades and Downgrades

VRTX has been the topic of several research reports. HC Wainwright cut their price objective on Vertex Pharmaceuticals from $550.00 to $478.00 and set a “buy” rating on the stock in a research note on Tuesday, August 5th. Canaccord Genuity Group lowered their price target on Vertex Pharmaceuticals from $424.00 to $411.00 and set a “hold” rating for the company in a report on Wednesday, August 6th. Royal Bank Of Canada dropped their price target on Vertex Pharmaceuticals from $423.00 to $415.00 and set a “sector perform” rating on the stock in a research report on Tuesday, November 4th. Barclays lifted their price objective on shares of Vertex Pharmaceuticals from $408.00 to $414.00 and gave the stock an “equal weight” rating in a report on Tuesday. Finally, Leerink Partners raised shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and dropped their target price for the stock from $458.00 to $456.00 in a report on Thursday, September 25th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $489.10.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.